doi:10.19803/j.1672-8629.2020.03.12

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2020.03.12

https://zgywjj.magtechjournal.com/EN/Y2020/V17/I3/184

[13] Dersimonian R, Laird N.Meta-analysis in clinical trials[J]. Control Clin Trials, 1986, 7(3): 177-188.
[14] Jackson D, Bowden J, Baker R.How does the DerSimonian and Laird procedure for random effects Meta-analysis compare with its more efficient but harder to compute counterparts?[J]. Journal of Statistical Planning and Inference, 2010, 140(4): 961-970.
[15] Inthout J, Ioannidis J P, Borm G F.The Hartung-Knapp-Sidik- Jonkman method for random effects Meta-analysis is straightfo- rward and considerably outperforms the standard DerSimonian- Laird method[J]. BMC Medical Research Methodology, 2014, 14(1): 25.
[16] Stanley T D, Doucouliagos H.Neither fixed nor random: weighted least squares Meta-analysis[J]. Statistics in Medicine, 2015, 34(13): 2116-2127.
[17] Higgins J P, Thompson S G.Quantifying heterogeneity in a Meta- analysis[J]. Stat Med, 2002, 21(11): 1539-1558.
[18] Sutton A J, Abrams K R.Bayesian methods in Meta-analysis and evidence synthesis[J]. Stat Methods Med Res, 2001, 10(4): 277-303.
[19] Little R, Rubin D.Statistical Analysis with Missing Data.[M]. Oxford, England: Wiley-Interscience, 2002.
[20] Pogue J M, Yusuf S.Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative Meta-analysis[J]. Controlled Clinical Trials, 1997, 18(6): 580-593.
[21] Van Der Tweel I, Bollen C. Sequential Meta-analysis: an efficient decision-making tool[J]. Clinical Trials, 2010, 7(2): 136-146.
[22] Whitehead A.A prospectively planned cumulative Meta-analysis applied to a series of concurrent clinical trials[J]. Statistics in medicine, 1997, 16(24): 2901-2913.
[23] Brok J, Thorlund K, Gluud C, et al.Trial sequential analysis reveals insufficient information size and potentially false positive results in many Meta-analyses[J]. J Clin Epidemiol, 2008, 61(8): 763-769.
[24] Higgins J P, Whitehead A, Simmonds M.Sequential methods for random-effects Meta-analysis[J]. Stat Med, 2011, 30(9): 903-921.
[25] Imberger G, Wetterslev J, Gluud C.Trial sequential analysis has the potential to improve the reliability of conclusions in Meta-analysis[J]. Contemp Clin Trials, 2013, 36(1): 254-5.
[26] Kulinskaya E, Wood J.Trial sequential methods for Meta- analysis[J]. Res Synth Methods, 2014, 5(3): 212-220.
[27] Miladinovic B, Mhaskar R, Hozo I, et al.Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error[J]. J Clin Epidemiol, 2013, 66(6): 654-659.
[28] Thorlund K, Devereaux P J, Wetterslev J, et al.Can trial sequential monitoring boundaries reduce spurious inferences from Meta- analyses?[J]. Int J Epidemiol, 2009, 38(1): 276-286.
[29] Wetterslev J, Thorlund K, Brok J, et al.Trial sequential analysis may establish when firm evidence is reached in cumulative Meta-analysis[J]. J Clin Epidemiol, 2008, 61(1): 64-75.
[30] Lau J, Schmid C H, Chalmers T C.Cumulative Meta-analysis of clinical trials builds evidence for exemplary medical care[J]. J Clin Epidemiol, 1995, 48(1): 45-57.
[31] Berlin J A, Crowe B J, Whalen E, et al.Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions[J]. Clin Trials, 2013, 10(1): 20-31.
[32] Thompson S G.Why sources of heterogeneity in Meta-analysis should be investigated[J]. Bmj, 1994, 309(6965): 1351-1355.
[33] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemi- ological studies[J]. Lancet, 1996, 347(9017): 1713-1727.
[34] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.
[J]. Lancet, 1997, 350(9084): 1047-1059.

[1]	ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913.
[2]	QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
[3]	LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
[4]	ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
[5]	LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793.
[6]	LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
[7]	YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
[8]	LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
[9]	ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.
[10]	LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
[11]	SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414.
[12]	ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
[13]	YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028.
[14]	SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
[15]	WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics